Business
GT Biopharma Announces Publication of GTB-3550 TriKE Interim Results at the Prestigious 62nd American Society of Hematology (ASH) Annual Meeting
TAMPA, FL / ACCESSWIRE / November 12, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"TAMPA, FL / ACCESSWIRE / November 12, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology is pleased to announce its abstract \"GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts\" has been selected by the Program Committee for presentation in an Oral Session at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition as detailed below:Session Name: 704. Immunotherapies: Beyond T to NKSession Date: Saturday, December 5, 2020Session Time: 7:30 AM - 9:00 AM Eastern TimePresentation Time: 8:00 AM Eastern TimeIn addition to the presentation, the abstract will also be published online in November supplemental issue of the journal Blood. First publication will be in the online ASH meeting program on November 5, 2020 (https://ash.confex.com/ash/2020/webprogram/Paper136398.html).Relapsed/refractory AML and MDS present a clinical challenge. Despite FDA approval of multiple new targeted agents, many patients lack actionable mutations and have exhausted conventional chemotherapeutic options.Patients with CD33+ malignancies (primary induction failure or relapsed AML with failure of one reinduction attempt or high risk MDS progressed on two lines of therapy) age 18 and older are eligible (NCT03214666). The primary endpoint is to identify the maximum tolerated dose (MTD) of GTB-3550 TriKE. Correlative objectives include the number, phenotype, activation status and function of NK cells and T cells.To date, 7 patients have been enrolled, two at 5 mcg/kg/day, two at 10 mcg/kg/day, two at 25 mcg/kg/day, and one at 50 mcg/kg/day. Six patients (5-25 mcg/kg/day) have completed therapy to date, with one patient (50mcg/kg/day) entering their third week of therapy. The first patient at 5 mcg/kg/day had stable disease after course 1 of GTB-3550 therapy, and the first patient at 25 mcg/kg/day saw AML blast levels decrease from 18% to 12% by morphological analysis after course 1 of GTB-3550 therapy.Of particular note, the previous reported MTD of continuous infusion rhIL-15 was 2 mcg/kg/day (Waldmann, TA et al, Clin Cancer Res. (2019) 25:4945-54) was associ...